Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406586 · ClinicalTrials.gov registry record · NA
Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02406586 is a NA study that has completed, run by Emory University. The registered enrollment target is 36 participants.
The verdict
NCT02406586, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to see if salsalate, an Nuclear factor-kappaB (NF-κB) mediated inflammation inhibitor, or carvedilol, an α- and β-blocker, will protect against free fatty acid induced hypertension, insulin resistance, endothelial dysfunction, inflammation and oxidative stress, and autonomic dysfunction in obese normotensive subjects.
Interventions
- DRUG Placebo
- DRUG Carvedilol
- DRUG Salsalate
- DRUG Intralipid 20%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406586
The ClinicalTrials.gov registry entry for NCT02406586 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02406586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406586 about?
NCT02406586 is a clinical study titled "Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)". The purpose of this study is to see if salsalate, an Nuclear factor-kappaB (NF-κB) mediated inflammation inhibitor, or carvedilol, an α- and β-blocker, will protect against free fatty acid induced hypertension, insulin resistance, endothelial dysfunction, inflammation and oxidative stress, and auton...
What is the current status of trial NCT02406586?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2009-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT02406586?
The interventions under investigation include: Placebo (DRUG), Carvedilol (DRUG), Salsalate (DRUG), Intralipid 20% (DRUG).
Who is sponsoring clinical trial NCT02406586?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.